Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Stadtmauer

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 15, 2001
Infectious complications the year after autologous bone marrow transplantation or peripheral stem cell transplantation for treatment of breast cancerT Barton, T Collis, E Stadtmauer, et al.
Blood|August 15, 1996
Bone marrow purging with oligodeoxynucleotidesA M Gewirtz, S M Luger, E Stadtmauer
Annals of the New York Academy of Sciences|March 20, 1993
Detection of bone marrow breast carcinoma metastasis using multiparameter flow cytometryC V Clevenger, M Khandewal, E Stadtmauer, et al.
Blood|September 15, 1993
bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemiaM Hanada, D Delia, A Aiello, et al.
Bone Marrow Transplantation|September 14, 1999
Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantationD Tsai, H Moore, C Hardy, et al.
Progress in Clinical and Biological Research|January 1, 1994
4-Hydroperoxycyclophosphamide purged autologous bone marrow transplantation of relapsed, responding non-Hodgkin's lymphoma with granulocyte colony stimulating factor support results in reliable hematopoietic recoveryD Biggs, E Stadtmauer, P Mangan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphomaM E Juweid, E Stadtmauer, G Hajjar, et al.
Journal of Hematotherapy & Stem Cell Research|July 14, 2000
Soluble interleukin-2 receptor concentration as a biochemical indicator for acute graft-versus-host disease after allogeneic bone marrow transplantationC Mathias, R Mick, S Grupp, et al.
Bone Marrow Transplantation|November 15, 2011
Potential prolongation of PFS in mantle cell lymphoma after R-HyperCVAD: auto-SCT consolidation or rituximab maintenanceT Ahmadi, J McQuade, D Porter, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 14, 1997
A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphomaD P Schenkein, D Roitman, K B Miller, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 15, 2001
Infectious complications the year after autologous bone marrow transplantation or peripheral stem cell transplantation for treatment of breast cancerT Barton, T Collis, E Stadtmauer, et al.
Blood|August 15, 1996
Bone marrow purging with oligodeoxynucleotidesA M Gewirtz, S M Luger, E Stadtmauer
Annals of the New York Academy of Sciences|March 20, 1993
Detection of bone marrow breast carcinoma metastasis using multiparameter flow cytometryC V Clevenger, M Khandewal, E Stadtmauer, et al.
Blood|September 15, 1993
bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemiaM Hanada, D Delia, A Aiello, et al.
Bone Marrow Transplantation|September 14, 1999
Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantationD Tsai, H Moore, C Hardy, et al.
Progress in Clinical and Biological Research|January 1, 1994
4-Hydroperoxycyclophosphamide purged autologous bone marrow transplantation of relapsed, responding non-Hodgkin's lymphoma with granulocyte colony stimulating factor support results in reliable hematopoietic recoveryD Biggs, E Stadtmauer, P Mangan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphomaM E Juweid, E Stadtmauer, G Hajjar, et al.
Journal of Hematotherapy & Stem Cell Research|July 14, 2000
Soluble interleukin-2 receptor concentration as a biochemical indicator for acute graft-versus-host disease after allogeneic bone marrow transplantationC Mathias, R Mick, S Grupp, et al.
Bone Marrow Transplantation|November 15, 2011
Potential prolongation of PFS in mantle cell lymphoma after R-HyperCVAD: auto-SCT consolidation or rituximab maintenanceT Ahmadi, J McQuade, D Porter, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 14, 1997
A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphomaD P Schenkein, D Roitman, K B Miller, et al.
Pageof 2